{"url_path":"/sec/lrmr/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1374690/0001193125-26-224087-index.html","accession_number":"0001193125-26-224087","cik":"0001374690","ticker":"LRMR","issuer_name":"Larimar Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1374690/0001193125-26-224087-index.html","primary_entity_key":"0001374690","primary_entity_name":"Larimar Therapeutics, Inc."},"word_count":1865,"has_tables":true,"body_markdown":"10-Q\n\nfalseQ10001374690--12-31http://fasb.org/srt/2025#ChiefExecutiveOfficerMemberhttp://fasb.org/us-gaap/2025#UsefulLifeTermOfLeaseMemberthree years2023-08-310001374690us-gaap:LeaseholdImprovementsMember2026-03-310001374690us-gaap:RetainedEarningsMember2026-01-012026-03-310001374690us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001374690lrmr:InducementStockMember2026-03-310001374690us-gaap:RestrictedStockUnitsRSUMember2025-12-3100013746902026-01-012026-03-310001374690us-gaap:PreferredStockMember2026-03-310001374690us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-310001374690us-gaap:CommonStockMembersrt:MaximumMember2026-03-310001374690us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001374690us-gaap:FairValueInputsLevel1Member2025-12-310001374690us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001374690us-gaap:CommonStockMemberlrmr:PermittedIncreaseUpon60DayNoticeMembersrt:MaximumMember2026-03-310001374690us-gaap:CommonStockMember2025-12-310001374690stpr:PAlrmr:LabSpaceMember2024-05-100001374690us-gaap:CommonStockMemberlrmr:FollowOnOfferingWithOverAllotmentOptionMember2025-07-012025-07-310001374690us-gaap:CommonStockMemberlrmr:FollowOnOfferingWithOverAllotmentOptionMember2026-02-280001374690us-gaap:ComputerEquipmentMember2026-03-310001374690us-gaap:EquipmentMember2026-03-310001374690us-gaap:FurnitureAndFixturesMember2025-12-310001374690lrmr:USGovernmentSecuritiesMember2026-03-310001374690lrmr:OfficeSubleaseMemberstpr:MAlrmr:FirstSubleaseYearMember2020-10-270001374690lrmr:TechnicalOperationsExpenseMember2025-01-012025-03-310001374690us-gaap:RetainedEarningsMember2024-12-310001374690stpr:MAlrmr:OfficeMemberus-gaap:LetterOfCreditMember2020-05-280001374690lrmr:OfficeSubleaseMemberstpr:MAlrmr:FinalSubleaseYearMember2020-10-270001374690us-gaap:CommonStockMemberlrmr:TwoThousandTwentyEquityIncentivePlanMember2026-03-310001374690us-gaap:SeriesAPreferredStockMember2025-12-310001374690us-gaap:MoneyMarketFundsMember2026-03-310001374690us-gaap:AdditionalPaidInCapitalMember2024-12-310001374690lrmr:USGovernmentSecuritiesMember2025-12-310001374690us-gaap:RestrictedStockUnitsRSUMemberlrmr:TwoThousandTwentyEquityIncentivePlanMemberlrmr:EmployeesMember2026-01-012026-03-3100013746902026-05-120001374690lrmr:UnvestedPerformance-BasedRestrictedCommonStockMember2025-01-012025-03-310001374690us-gaap:FairValueInputsLevel1Member2026-03-310001374690us-gaap:GeneralAndAdministrativeExpenseMember2026-01-012026-03-310001374690us-gaap:ComputerEquipmentMember2025-12-310001374690us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001374690srt:MaximumMember2025-01-012025-03-310001374690stpr:PAlrmr:OfficeMember2023-09-010001374690us-gaap:PreferredStockMember2025-12-3100013746902025-01-012025-03-310001374690lrmr:TwoThousandTwentyEquityIncentivePlanMembersrt:ExecutiveOfficerMemberlrmr:JanuaryTwentyTwentyFivePerformance-BasedRestrictedStockUnitAwardsMember2025-01-012025-03-310001374690us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2026-03-310001374690stpr:PAlrmr:OfficeMember2019-08-080001374690lrmr:EmployeesAndDirectorsMemberus-gaap:CommonStockMemberlrmr:TwoThousandTwentyEquityIncentivePlanMemberlrmr:FirstAnniversaryMember2026-01-012026-03-310001374690lrmr:CommercialExpenseMember2025-01-012025-03-310001374690us-gaap:FairValueInputsLevel2Member2026-03-310001374690stpr:PAlrmr:AdditionalOfficeMember2023-10-010001374690us-gaap:CommonStockMember2026-01-012026-03-310001374690srt:MaximumMember2026-01-012026-03-310001374690us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001374690stpr:PAlrmr:LabSpaceMember2023-10-162023-10-160001374690us-gaap:FurnitureAndFixturesMember2026-03-310001374690lrmr:TwoThousandTwentyEquityIncentivePlanMembersrt:ExecutiveOfficerMemberlrmr:JanuaryTwentyTwentyFivePerformance-BasedRestrictedStockUnitAwardsMember2026-01-012026-03-310001374690lrmr:InducementStockMember2026-01-012026-03-310001374690lrmr:GeneralAndAdministrativeRelatedStockCompensationExpenseMember2025-01-012025-03-310001374690us-gaap:SeriesAPreferredStockMember2025-12-012025-12-310001374690us-gaap:CommonStockMemberlrmr:TwoThousandTwentyEquityIncentivePlanMember2025-01-012025-01-010001374690srt:MaximumMemberlrmr:IndianaUniversityResearchAndTechnologyCorporationMember2016-11-300001374690lrmr:ResearchAndDevelopmentRelatedStockCompensationExpenseMember2026-01-012026-03-3100013746902026-03-310001374690us-gaap:MoneyMarketFundsMember2025-12-310001374690lrmr:OfficeSubleaseMemberstpr:MAlrmr:SixthSubleaseYearMemberus-gaap:LetterOfCreditMember2020-10-270001374690us-gaap:RetainedEarningsMember2025-03-310001374690us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310001374690us-gaap:CommonStockMember2025-12-012025-12-310001374690us-gaap:FairValueInputsLevel2Member2025-12-310001374690us-gaap:RestrictedStockUnitsRSUMember2026-03-310001374690us-gaap:GeneralAndAdministrativeExpenseMember2025-01-012025-03-310001374690us-gaap:CommonStockMemberlrmr:FollowOnOfferingWithOverAllotmentOptionMember2026-02-012026-02-280001374690stpr:PAlrmr:OfficeMember2026-01-012026-03-310001374690stpr:PAlrmr:OfficeMember2025-11-242025-11-240001374690us-gaap:CommonStockMember2025-03-310001374690us-gaap:AdditionalPaidInCapitalMember2025-03-310001374690lrmr:UnvestedPerformance-BasedRestrictedCommonStockMember2026-01-012026-03-310001374690srt:MaximumMemberlrmr:IndianaUniversityResearchAndTechnologyCorporationMember2019-12-112019-12-110001374690lrmr:ResearchAndDevelopmentRelatedStockCompensationExpenseMember2025-01-012025-03-310001374690us-gaap:CommonStockMemberlrmr:AtTheMarketEquityOfferingProgramMember2026-03-310001374690stpr:PAlrmr:OfficeMember2019-08-082019-08-0800013746902025-01-012025-12-310001374690us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-3100013746902024-12-310001374690us-gaap:CommonStockMemberlrmr:TwoThousandTwentyEquityIncentivePlanMember2026-01-012026-01-010001374690us-gaap:EquipmentMember2025-12-310001374690us-gaap:CommonStockMemberlrmr:FollowOnOfferingWithOverAllotmentOptionMember2025-07-310001374690lrmr:TwoThousandTwentyEquityIncentivePlanMemberlrmr:FromPriorPlansMember2026-01-012026-03-310001374690us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001374690us-gaap:ResearchAndDevelopmentExpenseMemberlrmr:IndianaUniversityResearchAndTechnologyCorporationMember2022-10-012022-10-310001374690lrmr:TwoThousandTwentyEquityIncentivePlanMember2026-01-012026-03-310001374690lrmr:EmployeesAndDirectorsMemberlrmr:TwoThousandTwentyEquityIncentivePlanMemberus-gaap:CommonStockMember2026-01-012026-03-310001374690us-gaap:GeneralAndAdministrativeExpenseMember2026-01-012026-03-310001374690us-gaap:AdditionalPaidInCapitalMember2025-12-310001374690us-gaap:RetainedEarningsMember2025-12-310001374690stpr:PAlrmr:OfficeMember2023-03-092023-03-090001374690us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-12-310001374690lrmr:TwoThousandTwentyEquityIncentivePlanMemberlrmr:FromPriorPlansMember2025-01-012025-12-310001374690stpr:PAlrmr:LabSpaceMember2023-10-160001374690us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001374690stpr:MAlrmr:OfficeMember2020-05-282020-05-280001374690us-gaap:FairValueInputsLevel2Memberlrmr:USGovernmentSecuritiesMember2025-12-310001374690us-gaap:SeriesAPreferredStockMember2026-01-012026-03-310001374690us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2025-12-310001374690us-gaap:CommonStockMemberlrmr:TwoThousandTwentyEquityIncentivePlanMembersrt:ExecutiveOfficerMemberlrmr:JanuaryTwentyTwentyFivePerformance-BasedRestrictedStockUnitAwardsMember2026-03-310001374690us-gaap:RetainedEarningsMember2025-01-012025-03-3100013746902025-03-310001374690us-gaap:RetainedEarningsMember2026-03-310001374690us-gaap:AdditionalPaidInCapitalMember2026-03-310001374690lrmr:OfficeSubleaseMemberstpr:MAus-gaap:LetterOfCreditMemberlrmr:FirstSubleaseYearMember2020-10-270001374690us-gaap:CommonStockMember2026-03-310001374690us-gaap:CommonStockMember2024-12-310001374690us-gaap:SeriesAPreferredStockMember2026-01-012026-01-310001374690us-gaap:ResearchAndDevelopmentExpenseMember2026-01-012026-03-310001374690us-gaap:FairValueInputsLevel2Memberlrmr:USGovernmentSecuritiesMember2026-03-310001374690lrmr:DevelopmentExpenseMember2025-01-012025-03-310001374690lrmr:TwoThousandTwentyEquityIncentivePlanMembersrt:MaximumMember2026-03-310001374690lrmr:GeneralAndAdministrativeRelatedStockCompensationExpenseMember2026-01-012026-03-310001374690lrmr:CommercialExpenseMember2026-01-012026-03-310001374690us-gaap:EmployeeStockOptionMember2026-01-012026-03-310001374690lrmr:NomlabofuspSupportExpenseMember2026-01-012026-03-310001374690lrmr:TechnicalOperationsExpenseMember2026-01-012026-03-310001374690us-gaap:LeaseholdImprovementsMember2025-12-310001374690us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001374690lrmr:NomlabofuspSupportExpenseMember2025-01-012025-03-310001374690us-gaap:GeneralAndAdministrativeExpenseMember2025-01-012025-03-3100013746902025-12-310001374690lrmr:TwoThousandTwentyEquityIncentivePlanMemberlrmr:JanuaryTwentyTwentyFivePerformance-BasedRestrictedStockUnitAwardsMember2025-01-012025-01-310001374690lrmr:OfficeSubleaseMemberstpr:MA2020-10-272020-10-270001374690us-gaap:CommonStockMember2025-01-012025-03-310001374690stpr:MAlrmr:OfficeMemberus-gaap:LetterOfCreditMember2024-10-310001374690stpr:PAlrmr:AdditionalOfficeMember2023-03-092023-03-090001374690us-gaap:CommonStockMember2026-01-012026-01-310001374690us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-03-310001374690lrmr:DevelopmentExpenseMember2026-01-012026-03-310001374690lrmr:TwoThousandTwentyEquityIncentivePlanMember2026-03-310001374690us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-03-310001374690stpr:PAlrmr:AdditionalOfficeMember2025-11-242025-11-240001374690us-gaap:PreferredStockMember2026-01-012026-03-310001374690us-gaap:CommonStockMemberlrmr:AtTheMarketEquityOfferingProgramMembersrt:MaximumMember2024-05-012024-05-31xbrli:pureutr:sqftxbrli:sharesiso4217:USDxbrli:shareslrmr:Segmentlrmr:ExecutiveOfficeriso4217:USD\n\n \n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWashington, D.C. 20549\n\n \n\n \n\nForm 10-Q\n\n \n\n \n\n(Mark One)\n\n \n\n☒\n\nQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\n \n\nFor the quarterly period ended March 31, 2026\n\nor\n\n \n\n☐\n\nTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\n \n\nFor the transition period from ___ to ____\n\nCommission File Number: 001-36510\n\nLARIMAR THERAPEUTICS, INC.\n\n(Exact name of registrant as specified in its charter)\n\n \n\nDelaware\n\n20-3857670\n\n(State or other jurisdiction of\n\nincorporation or organization)\n\n(I.R.S. Employer\n\nIdentification No.)\n\n \n\n \n\nThree Bala Plaza East, Suite 506\n\n19004\n\nBala Cynwyd, PA\n\n(Zip Code)\n\n(Address of principal executive offices)\n\n \n\n \n\n(844) 511-9056\n\n(Registrant’s telephone number, including area code)\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\nTitle of each class\n\nTrading Symbol(s)\n\nName of each exchange on which registered\n\nCommon Stock, par value $0.001 per share\n\nLRMR\n\nThe Nasdaq Global Market\n\n \n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐\n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐\n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge accelerated filer\n\n☐\n\n \n\nAccelerated filer\n\n☐\n\nNon-accelerated filer\n\n☒\n\n \n\nSmaller reporting company\n\n☒\n\n \n\n \n\n \n\nEmerging growth company\n\n☐\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒\n\nAs of May 12, 2026, there were 103,882,937 shares of the registrant’s Common Stock, $0.001 par value per share, outstanding.\n\n \n\n \n\nCAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS\n\nStatements made in this Quarterly Report on Form 10-Q that are not statements of historical or current facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements discuss our business, operations and financial performance and conditions, as well as our plans, objectives and expectations for our business operations and financial performance and condition. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “positioned,” “potential,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. In addition, statements that “we believe” or similar statements reflect our beliefs and opinions on the relevant subject only. These forward-looking statements, which are subject to risks, uncertainties and assumptions about us, may include projections of our future financial performance, our anticipated growth strategies and anticipated trends in our business.\n\nYou should understand that the following important factors could affect our future results and could cause those results or other outcomes to differ materially from those expressed or implied in our forward-looking statements:\n\n•\nuncertainties in obtaining successful non-clinical or clinical results that reliably and meaningfully demonstrate safety, tolerability and efficacy profiles that are satisfactory to the U.S. Food and Drug Administration (“FDA”), European Medicines Agency (“EMA”) and other comparable regulatory authorities for marketing approval for nomlabofusp or any other product candidates that we may develop in the future and unexpected costs that may result therefrom;\n\n•\ndelays in patient recruitment for our clinical trials (including as a result of the impact of FDA approval of competitive products for the treatment of Friedreich's ataxia (“FA”), and/or the impact of other clinical trials of competitive products), delays as a result of clinical and non-clinical results and/or the FDA's request for additional information or studies (whether clinical or non-clinical), changes in clinical protocols, adverse events, regulatory restrictions, including clinical holds, and milestones for nomlabofusp;\n\n•\nour ability to successfully execute our ongoing open label trial and our planned Phase 3 global registration study, including the timing of site initiations and the rate of patient enrollment;\n\n•\nour ability to benefit from participating in the FDA’s Support for Clinical Trials Advancing Rare Disease Therapeutics (“START”) pilot program for the development of nomlabofusp;\n\n•\nour ability to benefit from the FDA’s Breakthrough Therapy Designation;\n\n•\nuncertainties associated with the clinical development and regulatory approval for nomlabofusp in the United States and in other countries, including potential delays in the commencement, enrollment and completion of clinical trials, the timing of a potential Biologics License Application (“BLA”) submission to the FDA or similar applications to be submitted to other countries for accelerated approval, including including uncertainties regarding whether the FDA will ultimately agree with our rolling BLA submission strategy, our ability to submit BLA modules on the intended timelines and our ability to supply to the FDA or to regulatory authorities in other countries all required data to review and accept an accelerated application, or any other product candidates that we may develop in the future;\n\n•\nthe difficulties and expenses associated with obtaining and maintaining regulatory approval for nomlabofusp or any other product candidates we may develop in the future, and the indication and labeling under any such approval;\n\n•\nhow long we can continue to fund our operations with our existing cash, cash equivalents and marketable securities and our estimates regarding future results of operations, financial position, research and development costs, capital requirements and our access and needs for additional financing;\n\n•\nour expectations regarding the use of proceeds from our recent and future financings, if any;\n\n \n\n \n\n•\nour ability, and the ability of third-party manufacturers we engage, to optimize, scale and validate nomlabofusp or any other product candidate’s manufacturing process and to manufacture sufficient quantities of clinical supplies, and, if approved, commercial supplies of nomlabofusp or any other product candidates that we may develop in the future and our ability to maintain our relationships and contracts with our key vendors and to identify and contract with alternate or secondary key vendors;\n\n•\nour ability to realize any value from nomlabofusp and/or any other product candidates we may develop in the future in light of inherent risks and difficulties involved in successfully bringing product candidates to market and the risk that the product candidates, if approved, will not achieve broad market acceptance;\n\n•\nour ability to comply with regulatory requirements applicable to our business and other regulatory developments in the United States and other countries;\n\n•\nthe size and growth of the potential markets for nomlabofusp, if approved, or any other product candidates that we may develop in the future, the rate and degree of market acceptance of nomlabofusp or any other product candidate, if approved, that we may develop in the future and our ability to serve those markets;\n\n•\ngiven both approved and competing therapies and products in non-clinical and clinical development for the treatment of FA, our ability to obtain and maintain designations or eligibility for expedited regulatory programs, and to commercialize current and future product candidates, if approved, (including the impact of potential barriers to entry if a competitor is able to establish and maintain a strong market position before we are able to commercialize our products);\n\n•\nour ability to obtain and maintain patent protection and defend our intellectual property rights against third parties;\n\n•\nthe performance and compliance with the rules and regulations of the FDA (and all other regulatory authorities) of third parties upon which we depend, including third-party contract research organizations (“CROs”), third party contract manufacturing organizations (\"CMOs\"), consultants, distributors, and logistics providers.\n\n•\nour ability to recruit and retain key scientific, technical, commercial, and management personnel and to retain our executive officers;\n\n•\nour ability to maintain proper functionality and security of our internal computer and information systems and prevent or avoid cyber-attacks, malicious intrusion, breakdown, destruction, loss of data privacy or other significant disruption;\n\n•\nthe extent to which geopolitical conflicts and tensions (including the war in the Middle East and other regional conflicts around the world), adverse macroeconomic events, including those due to inflationary pressures, rising interest rates, banking instability, monetary policy changes, changes in trade policies, (including tariffs or trade protection measures that have been or may in the future be imposed by the U.S. or other countries), economic slowdowns or recessions, health epidemics, unforeseen emergencies and other outbreaks of communicable diseases that could disrupt our operations, the operations of third parties on which we rely or the operations of regulatory agencies we interact with in the development of nomlabofusp and any other product candidates that we may develop in the future; and\n\n•\nthe potential impact of regulatory developments in the U.S., including regulatory developments due to changes in the U.S. presidential administration, healthcare reform in the United States, including the Inflation Reduction Act of 2022 (“IRA”), and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures.\n\n \n\n \n\nThese forward-looking statements are based on management’s current expectations, estimates, forecasts and projections about our business and the industry in which we operate, and management’s beliefs and assumptions are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Although we believe the expectations reflected in the forward-looking statements are reasonable, the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements may not be achieved or occur at all. The factors that could cause or contribute to such differences include, but are not limited to, those discussed in our Annual Report on Form 10-K filed on March 19, 2026. All forward-looking statements are applicable only as of the date on which they were made and, except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this Quarterly Report on Form 10-Q or to reflect the occurrence of any unanticipated events. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as historical data.\n\n \n\n \n\nLarimar Therapeutics, Inc.\n\nINDEX\n\n \n\n \n\n \n\nPage\n\n \n\n \n\n \n\n[PART I - FINANCIAL INFORMATION](#part_ifinancial_information)"}